In contrary to the reports mentioned above, in a study of 1333 Czech ovarian cancer patients and 152 borderline ovarian tumor cases recruited from seven centers, the prevalence of BRCA1/2 mutations was similar in high-grade ovarian cancers and BOT cases (30.9% and 28.9%) [14]. The gene discussed is BRCA1; the disease is ovarian carcinoma.